OptiNose Common Stock Total Equity from 2010 to 2024
| OPTN Stock | USD 0.54 0.03 5.88% |
Check OptiNose financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OptiNose's main balance sheet or income statement drivers, such as , as well as many indicators such as . OptiNose financial statements analysis is a perfect complement when working with OptiNose Valuation or Volatility modules.
OptiNose |
About OptiNose Financial Statements
OptiNose investors utilize fundamental indicators, such as Common Stock Total Equity, to predict how OptiNose Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania. Optinose operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.
Pair Trading with OptiNose
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OptiNose position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OptiNose will appreciate offsetting losses from the drop in the long position's value.Moving together with OptiNose Stock
| 0.75 | VALN | Valneva SE ADR | PairCorr |
| 0.62 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.83 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.72 | LLY | Eli Lilly Sell-off Trend | PairCorr |
Moving against OptiNose Stock
| 0.73 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.64 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.53 | GILD | Gilead Sciences | PairCorr |
| 0.31 | LPCN | Lipocine | PairCorr |
The ability to find closely correlated positions to OptiNose could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OptiNose when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OptiNose - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OptiNose to buy it.
The correlation of OptiNose is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OptiNose moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OptiNose moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OptiNose can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of OptiNose Correlation against competitors. To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OptiNose. If investors know OptiNose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OptiNose listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of OptiNose is measured differently than its book value, which is the value of OptiNose that is recorded on the company's balance sheet. Investors also form their own opinion of OptiNose's value that differs from its market value or its book value, called intrinsic value, which is OptiNose's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OptiNose's market value can be influenced by many factors that don't directly affect OptiNose's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OptiNose's value and its price as these two are different measures arrived at by different means. Investors typically determine if OptiNose is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OptiNose's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.